For: | Lee HS, Choi Y, Hur WJ, Kim HJ, Kwon HC, Kim SH, Kim JS, Lee JH, Jung GJ, Kim MC. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: Adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. World J Gastroenterol 2006; 12(4): 603-607 [PMID: 16489675 DOI: 10.3748/wjg.v12.i4.603] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v12/i4/603.htm |
Number | Citing Articles |
1 |
H. Abbas, Shimaa Ahmed, Ahmed A. S. Salem, Mohamed Abou Elmagd Salem, Mahmoud Hussin, Wessam A. El Sherief. Intravenous Fluorouracil versus Oral Capecitabine: Postoperative Chemoradiation for Gastric Cancer. Journal of Cancer Therapy 2015; 6(11): 954 doi: 10.4236/jct.2015.611103
|
2 |
Xin Wang, Wei-Hu Wang, Shu-Lian Wang, Yong-Wen Song, Yue-Ping Liu, Yuan Tang, Ning Li, Wen-Yang Liu, Hui Fang, Ye-Xiong Li, Dong-Bing Zhao, Yihebali Chi, Lin Yang, Jing Jin. Efficacy and toxicity of capecitabine combined with intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with gastric cancer. World Journal of Gastrointestinal Oncology 2021; 13(10): 1532-1543 doi: 10.4251/wjgo.v13.i10.1532
|
3 |
Karin Oechsle, Carsten Bokemeyer, Jörg T. Hartmann, Wilfried Budach, Tanja Trarbach, Michael Stahl, Ina Boehlke, Christian Kollmannsberger. Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO group. Journal of Cancer Research and Clinical Oncology 2009; 135(2): 163 doi: 10.1007/s00432-008-0463-6
|
4 |
Mercedes Martín Sánchez, Maria Ángeles Pérez Escutia, David Lora Pablos, Sandra Guardado Gonzales, Ana María Cabezas Mendoza, Arantxa Campos Bonel, Héctor Pérez Montero, Rafael D’Ambrosi, José Fermín Pérez-Regadera Gómez. Adjuvant radiochemotherapy in locally advanced gastric cancer. Strahlentherapie und Onkologie 2017; 193(12): 1005 doi: 10.1007/s00066-017-1173-2
|
5 |
Joshua D. Lawson, Jason K. Sicklick, Paul T. Fanta. Gastric Cancer. Current Problems in Cancer 2011; 35(3): 97 doi: 10.1016/j.currproblcancer.2011.03.001
|
6 |
Laura B. Vater, Bénédicte Lefebvre, Anita Turk, Suparna C. Clasen. Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge. Current Oncology Reports 2022; 24(7): 943 doi: 10.1007/s11912-022-01256-6
|
7 |
Jee Suk Chang, Woong Sub Koom, Youngin Lee, Hong In Yoon, Hyung Sik Lee. Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: Is radiotherapy necessary after D2-dissection?. World Journal of Gastroenterology 2014; 20(36): 12900-12907 doi: 10.3748/wjg.v20.i36.12900
|
8 |
A. Yoney, Y. Bati, H. Akboru, L. Isikli, M. Unsal. A retrospective comparison of concurrent 5-fluoro-uracil or oral UFT in postoperative chemoradiation for gastric adenocarsinoma. Cancer/Radiothérapie 2010; 14(1): 19 doi: 10.1016/j.canrad.2009.09.004
|
9 |
Joseph M. Caster, Joel E. Tepper. Gastrointestinal Malignancies. Practical Guides in Radiation Oncology 2018; : 53 doi: 10.1007/978-3-319-64900-9_3
|
10 |
Adnan Yoney, Levent Isikli. Can Capecitabine be used Instead of Concurrent Bolus 5-FU in Postoperative Chemoradiotherapy for Gastric Adenocarcinoma?. Asian Pacific Journal of Cancer Prevention 2013; 14(9): 5127 doi: 10.7314/APJCP.2013.14.9.5127
|
11 |
Jin Peng, Yuehua Wei, Fuxiang Zhou, Jing Dai, Yahua Zhong, Conghua Xie, Yue'e Qin, Jun Gong, Bin Xiong, Yunfeng Zhou. D2‐resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy. Cancer Medicine 2016; 5(10): 2773 doi: 10.1002/cam4.873
|
12 |
Linda Agolli, Riccardo Maurizi Enrici, Mattia Falchetto Osti. Adjuvant radiochemotherapy for gastric cancer: Should we use prognostic factors to select patients?. World Journal of Gastroenterology 2016; 22(3): 1131-1138 doi: 10.3748/wjg.v22.i3.1131
|
13 |
Kai-tai Liu, Jue-feng Wan, Gen-hua Yu, Yan-ping Bei, Xue Chen, Miao-zhen Lu. The recommended treatment strategy for locally advanced gastric cancer in elderly patients aged 75 years and older: a Surveillance, Epidemiology, and End Results database analysis. Journal of Cancer Research and Clinical Oncology 2017; 143(2): 313 doi: 10.1007/s00432-016-2289-y
|